Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 2

Sponsor Class

INDUSTRY 4NIH 2OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Other hematologic neoplasm 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 1Cytopenia 1

Interventions

Cytarabine 30fludarabine phosphate 19Specimen Handling 15Cyclophosphamide 15Biopsy 14Peripheral Blood Stem Cell Transplantation 13Busulfan 13Imatinib Mesylate 12Etoposide 12Filgrastim 11Decitabine 11Azacitidine 11Methotrexate 10Idarubicin 10Daunorubicin 10Cyclosporine 9X-Rays 8Tacrolimus 8Antilymphocyte Serum 8tipifarnib 7Vorinostat 7Stem Cell Transplantation 7Radiotherapy 7Magnetic Resonance Spectroscopy 7fludarabine 6decitabine and cedazuridine drug combination 6Phantoms, Imaging 6Topotecan 5Prednisone 5Nuclear Medicine Department, Hospital 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × cedazuridine × Myeloid × Clear all
NCT05918055 2025-12-02

Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
3 enrolled 9 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05148234 2025-09-30

BMS-986253 in Myelodysplastic Syndromes

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
2 enrolled 11 charts
Classical hematologyMyeloid

Cytopenia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡